BiotechTube

FK962

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease

Trial Timeline

Jul 1, 2004 → Sep 1, 2006

NCT ID
NCT00087724

About FK962

FK962 is a phase 2 stage product being developed by Astellas Pharma for Alzheimer's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00087724. Target conditions include Alzheimer's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00087724Phase 2Terminated

Competing Products

20 competing products in Alzheimer's Disease

See all competitors
ProductCompanyStageHype Score
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
GSK4527226AlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
simufilamCassava SciencesPhase 2
44
Remternetug + PlaceboEli LillyPhase 3
77
solanezumabEli LillyPhase 2
52
LY2886721 + PlaceboEli LillyPhase 1
33
Gantenerumab + Gantenerumab + Gantenerumab + PlaceboChugai PharmaceuticalPhase 1
33
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
85
ASP0777 + PlaceboAstellas PharmaPhase 1
33
Elenbecestat + PlaceboEisaiPhase 3
77
DonepezilEisaiApproved
85
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)EisaiPhase 3
77
Donepezil hydrochlorideEisaiPhase 3
77
Donepezil HydrochlorideEisaiPre-clinical
23
Lecanemab IV + Placebo + Lecanemab SCEisaiPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85